NutraSift: The nutraceutical innovation podcast

Elderberry cyanidin glycosides inhibit viral neuraminidase the same mechanism as oseltamivir (Tamiflu). That's a specific, defined, anti-viral target. But the industry markets elderberry as generic "immune support" because regulators won't allow anti-viral claims on a food supplement. The mechanism is there. The IP is there. The claim structure isn't. Publications of interest...

Intravenous silibinin (Legalon SIL) is the standard of care for Amanita phalloides mushroom poisoning in European hospitals. Milk thistle is one of the only botanical ingredients that has crossed the line from supplement to emergency medicine. That level of clinical validation is almost unique in the natural products space. Publications of interest: https://pubmed.ncbi.nlm.nih.gov/22352731/ https:...

Silymarin contains two isomers of silybin (A and B) with different 3D configurations and different biological activity. No commercial standardization distinguishes between them. A product optimized for the more potent isomer on metabolic targets would be a genuinely novel ingredient from a plant used for 2,000 years. Publications of interest: https://pubmed.ncbi.nlm.nih.gov/22224281/ https://pubme...

Silymarin has been "the liver ingredient" for 2,000 years. But silybin (the most active flavonolignan in silymarin) activates IRS-1 phosphorylation and GLUT4 translocation core mechanisms of insulin sensitivity and glucose uptake. With 25% of the global population having NAFLD/MAFLD, the metabolic health repositioning of silymarin could be worth more than its entire current liver health...

Grape seed extract comes from pomace ,the leftover skins, seeds, and stems from winemaking. Bordeaux alone produces enough pomace annually to supply the global OPC market many times over. It's one of the few botanical ingredients where the supply chain is up-cycled agricultural waste. And yet it's not marketed that way. Publications of interest: https://pmc.ncbi.nlm.nih.gov/articles/PMC114...

Grape seed OPCs (oligomeric proanthocyanidins) come in dimers, trimers, and higher polymers. Dimers and trimers are absorbed intact and have direct vascular effects (NO pathway). Higher polymers are fermented by gut bacteria into phenylvalerolactones with their own bioactivity. The entire grape seed market standardizes on "% total polyphenols" ignoring that the chain length determines wh...

Most green tea extract supplements say "antioxidant." The actual mechanism that drives weight management results is COMT inhibition (extending norepinephrine activity) + AMPK activation (thermogenesis). Those are pharmacological actions, not "antioxidant properties." Selling EGCG as an antioxidant is like selling aspirin as a headache remedy and ignoring its cardiovascular mech...

L-theanine ,the amino acid that promotes alpha brain wave activity, is naturally co-present with EGCG in green tea. The calming focus of tea (vs. the jitteriness of coffee) is an L-theanine effect, not a catechin effect. Yet the entire green tea extract market is standardized on catechins/EGCG. The L-theanine is stripped out during most extraction processes. You extract the antioxidant but discard...

EFSA set an 800mg/day upper limit for EGCG after reviewing hepatotoxicity cases. Some concentrated supplements deliver 400-500mg per capsule. Two capsules and you're above the safety limit. The same ingredient with 10,000+ studies proving benefit also has a documented signal for liver damage at doses that many products comfortably deliver. The therapeutic window is narrower than the market ack...

Salidroside modulates HIF-1alpha (hypoxia-inducible factor). This is the master switch for oxygen sensing in cells. No other adaptogen directly targets this pathway. That's why rhodiola has unique data on altitude performance, fatigue under hypoxic conditions, and VO2max enhancement that ashwagandha and ginseng don't match. Publications of interest: https://pubmed.ncbi.nlm.nih.gov/34739769...

E. purpurea (chicoric acid + alkamides), E. angustifolia (echinacoside + alkamides), E. pallida (echinacoside, few alkamides). These are pharmacologically different plants with different mechanisms sold interchangeably as "Echinacea." It's as if someone sold Arabica, Robusta, and Liberica as interchangeable "coffee" for clinical purposes. Publications of interest: https://p...

Cochrane reviews on echinacea for colds show mixed results. But most clinical trials used products standardized on polysaccharides or caffeic acid derivatives NOT alkamides. The alkamide-CB2 mechanism is the most pharmacologically compelling, the best-absorbed (lipophilic), and the least-studied in humans. We might be dismissing a $2B ingredient based on trials that tested the wrong fraction. Publ...

Echinacea alkamides (isobutylamides) interact directly with CB2 endocannabinoid receptors. This makes echinacea technically an endocannabinoid system modulator, the same receptor system targeted by CBD. Yet the entire echinacea market is standardized on polysaccharides or chicoric acid, and the alkamide fraction is literally discarded in most extraction processes. The CB2 story could reposition ec...

The GLP-1 drug market (Ozempic, Wegovy, Mounjaro) will be $268B by 2030. Oral GLP-1 agonists are in Phase 3 trials. When a consumer can take a $5/day pill that is an actual GLP-1 agonist, what happens to the "natural GLP-1 support" supplement market? The nutraceutical window for berberine's metabolic positioning is 2-3 years. Companies that don't lock in mechanism-specific patent...

Berberine's intense yellow color comes from its ability to intercalate into DNA. It literally slides between DNA base pairs. This same property explains its anti-microbial and anti-cancer mechanisms and also why it inhibits CYP3A4 (the same enzyme that metabolizes 50% of all drugs). The supplement industry rarely mentions that the same molecule that lowers blood sugar also creates significant...

The "nature's Ozempic" claim is based on AMPK activation, an indirect, downstream effect. But berberine (specifically dihydroberberine) appears to directly stimulate GLP-1 secretion from intestinal L-cells through a separate, AMPK-independent pathway. The real GLP-1 story is actually more compelling than the marketing claim, but it requires a mechanistic understanding most companies...

Alpha-boswellic acid, beta-boswellic acid, 11-keto-beta-boswellic acid, acetyl-beta-boswellic acid, each with different 5-LOX inhibition profiles and selectivity for downstream mediators. A boswellia extract optimized for microglial inflammation (brain) rather than systemic 5-LOX would be a different product, different IP, different market. Publications of Interest: https://pubmed.ncbi.nlm.nih.gov...

Incensole acetate, a compound found in boswellia resin (frankincense), activates TRPV3 ion channels in the brain and shows antidepressant and anxiolytic effects in animal models. It actually crosses the blood-brain barrier. Nobody in the supplement industry is talking about boswellia for mental health. Currently it is exclusively positioned for joints. The neuroinflammation angle is entirely virgi...

Curcumin, ginger, omega-3 they all target the COX pathway (same as ibuprofen). Boswellia (AKBA) is the only major botanical that selectively inhibits 5-lipoxygenase, a completely different inflammatory pathway producing leukotrienes, not prostaglandins. That's a unique mechanism shared with no other natural ingredient. Yet boswellia is marketed as "another joint ingredient" competing...

"Ashwagandha" means "smell of horse" (ashwa = horse, gandha = smell) , referring to the root's odor. But it's been romantically reinterpreted as "strength of a stallion" in modern marketing. The actual mechanism, HPA-axis modulation, cortisol reduction, and GABA-ergic activity however has nothing to do with horses. The evidence is real: the brand story is an a...

Most of ashwagandha's sleep marketing is based on cortisol-lowering data. But the actual sleep compound may be triethylene glycol, a simple organic molecule found in the leaf (not the root) that shows direct sleep-inducing activity in animal models via GABA-A modulation. KSM-66 uses only root. The sleep mechanism may be in the part of the plant the most popular extract throws away. Publication...

KSM-66: 5% withanolides. Shoden: 35% withanolides. Sensoril: 10% withanolide glycosides. These are three different products with different compounds at different ratios targeting different receptors , marketed as the same thing. Withaferin A inhibits NF-kB (anti-inflammatory). Withanolide D activates GABA-A (anxiolytic). Withanone targets the p53-mortalin interaction (anti-aging). "% total wi...

Commodity curcumin costs $3-34/kg. Meriva (Indena's phytosome curcumin) sells for 10-20x that. Same Curcuma longa. Same curcuminoid molecule. The difference: one mechanism study, one delivery patent, 40+ clinical trials, and a brand name. That transformation playbook is repeatable for every ingredient on this list. Publications of interest: https://pubmed.ncbi.nlm.nih.gov/21194249/, https://pm...

Curcumin's oral bioavailability is <1%. The industry has spent billions on delivery systems (phytosomes, nanoemulsions, piperine). But emerging evidence suggests that curcumin's gut metabolite - tetrahydrocurcumin - is the primary systemic active. If the metabolite is doing the work, the bioavailability "problem" might actually be the delivery mechanism. The entire patent land...

Bisdemethoxycurcumin makes up only ~3% of the curcuminoid complex, yet it's the most potent NF-kB inhibitor of the three curcuminoids. The dominant compound, curcumin itself (~77%), is actually the weakest at nuclear translocation inhibition. The industry standardizes on "95% total curcuminoids", treating three molecules with different mechanisms as one. The company that fractionates...